CD40L Monoclonal Antidbody [MR1]
- Known as:
- CD40L Monoclonal Antidbody [MR1]
- Catalog number:
- A-0555-500
- Product Quantity:
- 500
- Category:
- -
- Supplier:
- EpigenTek
- Gene target:
- CD40L Monoclonal Antidbody [MR1]
Related genes to: CD40L Monoclonal Antidbody [MR1]
- Gene:
- AATK NIH gene
- Name:
- apoptosis associated tyrosine kinase
- Previous symbol:
- -
- Synonyms:
- AATYK, KIAA0641, LMTK1, LMR1, AATYK1, PPP1R77
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-16
- Date modifiied:
- 2016-06-29
- Gene:
- ADGRE1 NIH gene
- Name:
- adhesion G protein-coupled receptor E1
- Previous symbol:
- TM7LN3, EMR1
- Synonyms:
- -
- Chromosome:
- 19p13.3-p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-08-31
- Date modifiied:
- 2018-02-13
- Gene:
- ATP2C1 NIH gene
- Name:
- ATPase secretory pathway Ca2+ transporting 1
- Previous symbol:
- BCPM
- Synonyms:
- KIAA1347, ATP2C1A, PMR1, SPCA1
- Chromosome:
- 3q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-19
- Date modifiied:
- 2016-10-05
- Gene:
- CD40LG NIH gene
- Name:
- CD40 ligand
- Previous symbol:
- HIGM1, IMD3, TNFSF5
- Synonyms:
- CD40L, TRAP, gp39, hCD40L, CD154
- Chromosome:
- Xq26.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
- Gene:
- FAN1 NIH gene
- Name:
- FANCD2 and FANCI associated nuclease 1
- Previous symbol:
- KIAA1018, MTMR15
- Synonyms:
- -
- Chromosome:
- 15q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-10-28
- Date modifiied:
- 2016-12-21
Related products to: CD40L Monoclonal Antidbody [MR1]
Related articles to: CD40L Monoclonal Antidbody [MR1]
- Triple-negative breast cancer (TNBC) remains an aggressive disease with limited treatment options. Oncolytic adenoviruses represent a promising platform, but their efficacy as single agents is often insufficient. This study examined whether an oncolytic adenovirus co-delivering decorin (DCN) and CD40 ligand (CD40L), designated rAd.DCN.CD40L, could enhance antitumor activity and immune activation against TNBC. Recombinant adenoviruses expressing DCN (rAd.DCN), CD40L (rAd.CD40L), or both proteins were constructed and evaluated in breast cancer cells using cell viability, apoptosis, migration, invasion, and damage-associated molecular pattern (DAMP) release assays. Compared with rAd.DCN or rAd.CD40L alone, rAd.DCN.CD40L triggered greater apoptosis and tumor cell death and elicited more pronounced DAMP release. Co-culture experiments also revealed enhanced dendritic cell function following rAd.DCN.CD40L treatment. For in vivo evaluation, syngeneic 4T1 and EMT-6 subcutaneous tumor models and a 4T1 lung metastasis model were employed. rAd.DCN.CD40L substantially delayed tumor growth and improved survival in tumor-bearing mice. Flow cytometric and histological analyses further confirmed enhanced local and systemic T-cell responses, elevated CD8⁺ T-cell activity, and modulated inflammatory macrophage phenotypes. Mechanistically, western blot analysis showed that rAd.DCN.CD40L may contribute to extracellular matrix remodeling and the down-regulation of the expression of epithelial-mesenchymal transition (EMT)-associated genes. Notably, CD8⁺ T-cell depletion markedly attenuated the therapeutic efficacy of rAd.DCN.CD40L, demonstrating that CD8⁺ T cells are critical functional effectors of tumor control. Collectively, these findings indicate that a DCN- and CD40L-armed oncolytic adenovirus represents a promising combinatorial strategy for TNBC immunotherapy, and warrants further preclinical and clinical investigation. - Source: PubMed
Publication date: 2026/10/05
Ning YingjunRong YejingMeng HaifengLin YudongChen WanqianShi QiaoyunZhang SijiaLi HongshanYang Yuefeng - The CD40L molecule is primarily expressed on the activated CD4 T lymphocytes and plays a key role in the immune response. Upon contact with a B lymphocyte, CD40L binds to the CD40 receptor and triggers signaling pathways, leading to B cell proliferation and differentiation and inducing a switch in Ig synthesis. When using soluble forms of CD40L as an activator, preliminary forced multimerization of CD40L is a prerequisite. A construct in which the receptor-binding domain of CD40L is fused to the collagen-like domain of adiponectin (Adn) is often used to multimerize CD40L. It is believed that Adn-CD40L forms several oligomeric forms. In our study, we obtained an Adn-CD40L preparation from which we isolated the low-molecular-weight and high-molecular-weight forms of Adn-CD40L (LMW and HMW). We next studied their biochemical, structural, and functional characteristics. It was concluded that LMW is a trimer of Adn-CD40L, while HMW is a mixture of higher-order oligomers. LMW demonstrated higher activity in the NF-κB-dependent signaling pathway activation assays compared to HMW. However, HMW induced more pronounced B-cell expansion and stimulated Ig secretion to a greater extent than LMW. These results could be used to develop new CD40L-based immunotherapeutics. - Source: PubMed
Mikhailov Artem AByazrova Maria GSukhova Maria MPetukhov Maxim VShtykova Eleonora VFilatov Alexander V - This clinical trial sought to determine whether SL-172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher-risk myelodysplastic syndrome (HR-MDS) or acute myeloid leukemia (AML). - Source: PubMed
Daver Naval GZeidan Amer MStein Anthony SZeidner Joshua FMaher KeriCurran EmilyBixby DaleChai-Ho WanxingStahl MaximilianYee Karen W LStevens DonIto SawaReynolds JanaMedd PatrickSearle EmmaSochacki AndrewSavoie Mary LynnGreen StevenKato KazunobuHernandez RobertMetenou SimonMa BoPandite LiniSchreiber Taylor HSallman David A - Southwestern local chicken breeds in China have long been recognized for their strong adaptability and disease resistance, shaped by unique selective pressures during domestication. In this study, we combined Fst and π ratio analyses to detect selection signatures from RAD-seq data of four southwestern local breeds, Red Junglefowl, and 17 other Chinese local breeds. We identified 460 candidate genes under strong selection potentially associated with domestication, affecting behaviors, physiology, reproduction, immunity, and adaptability. Importantly, 34 genes showed strong and unique selection signals when comparing southwestern breeds with other local breeds. Among these, , , and represent candidate genes that have been previously associated with immune processes, while , , and represent candidate genes potentially related to disease resistance. Furthermore, , and represent candidate genes potentially associated with environmental adaptability. Notably, , the only gene detected across all comparison groups, may reflect morphological adaptation related to feeding efficiency. Our findings provide valuable insights into the genetic basis of unique adaptations in southwestern local chicken breeds and highlight potential targets for breeding and conservation. - Source: PubMed
Publication date: 2026/09/09
Wang MengyuZou MingyangZhou ChenghaoHan Wei - Clinical xenotransplantation offers a conceptually unlimited supply of donor organs, owing to transformative advances in gene-editing technologies. However, the pharmacological and physiological distinctions between allo- and xenotransplantation pose a major challenge. Unlike allografts, xenografts simultaneously trigger complement-amplified humoral rejection, thromboregulatory incompatibility driven by porcine-human molecular mismatch, and species-specific innate inflammatory cascades. However, conventional calcineurin-based immunosuppression provides no meaningful coverage for these pathways. We analyzed these differences to provide the mechanistic foundation for a dedicated perioperative framework. The proposed framework encompasses immunologic assessment; porcine cytomegalovirus (PCMV)/roseolovirus-free donor certification; intensified induction; third-generation anti-CD154 monoclonal antibodies with pharmacokinetically verified trough targets; normothermic machine perfusion with anti-inflammatory perfusate supplementation; and thromboregulatory rescue protocols incorporating tranexamic acid, heparin, and antiplatelet agents. Furthermore, we aimed to address consumptive coagulopathy; targeted suppression of macrophage- and neutrophil-driven innate inflammatory cascades, alongside activation of xenoreactive natural killer cells; and multimodal surveillance integrating flow cytometry, donor-derived cell-free DNA, and metagenomic sequencing for porcine endogenous retrovirus and PCMV monitoring. By combining compassionate-use failure analysis with prospective trial design aligned with the 2026 International Society for Heart and Lung Transplantation consensus statement, this review proposes a standardized perioperative management protocol that is applicable to clinical xenotransplantation. - Source: PubMed
Publication date: 2026/09/22
Han Kyu-HyunYang Jaeseok